CCLG produced or endorsed guidelines will be published here.
The full range of CCLG treatment guidelines, guidance and recommendations is available to CCLG members on the member area of the website.
Referral guidance for suspected cancer in children and young people
A supporting resource for NICE guideline NG12 - Suspected cancer: recognition and referral
This document is a supplement to the NICE guidelines for suspected cancer: recognition and referral (NG12). The NICE guideline covers the identification of symptoms that could be caused by cancer in people of all ages. It outlines appropriate investigations in primary care and selection of people to refer for specialist opinion. Our guidance is specific to children as it is recognised that there are a number of differences in the presentation, referral pathways and care of children with cancer compared with those of adults.
Referral guidance for suspected cancer in children and young people
This booklet accurately reflects recommendations in the NICE guidance on recognition and referral for suspected cancer.
National Institute for Health and Care Excellence April 2021
Rare endocrine tumour guidelines
Our rare endocrine tumour guidelines are intended to be a reference document for clinicians presented with the challenge of managing children and young people with rare endocrine tumour diagnoses. In total, a series of eight guidelines are in development. So far we have published guidelines for craniopharyngioma and idiopathic thickened pituitary stalk (iTPS) and/or idiopathic central diabetes insipidus (CDI).
Rare endocrine tumour guidelines
Vaccinations For Paediatric Patients Treated With Standard-Dose Chemotherapy And Haemopoietic Stem Cell Transplantation (HSCT) Recipients
This results in increased susceptibility to and severity of infections. Most vaccine-preventable diseases (VPD) are now fortunately rare; however, the risk for some remains significant, in part because of increases in migration and travel, and poor vaccine update. VPD can be associated with high morbidity and mortality, particularly in immunocompromised patients. In view of the immune deficiency of children treated for cancer, particularly HSCT recipients, it is important to ensure that they are protected against VPD both during and after completion of treatment. This can be achieved by optimising the vaccination strategy in children during immunosuppressive therapy, and after completion of treatment at a time point that balances immune recovery to avoid vaccine side effects (especially for live vaccines) and enable optimal immune responses.